0 244

Cited 2 times in

Neointimal response to second-generation drug-eluting stents in diabetic patients with de-novo coronary lesions: intravascular ultrasound study

 Won, Hoyoun  ;  Kang, Tae Soo  ;  Hong, Bum-Kee  ;  Lee, Seunghwan  ;  Jeon, Dong Woon  ;  Ryu, Sung Kee  ;  Min, Pil-Ki  ;  Yoon, Young Won  ;  Lee, Byoung Kwon  ;  Kwon, Hyuck Moon  ;  Ko, Young-Guk  ;  Jang, Yangsoo 
 CORONARY ARTERY DISEASE, Vol.26(3) : 212-219, 2015 
Journal Title
Issue Date
Aged ; Cardiovascular Agents/administration & dosage* ; Coronary Angiography ; Coronary Restenosis/diagnostic imaging ; Coronary Restenosis/etiology ; Coronary Restenosis/pathology ; Coronary Restenosis/prevention & control* ; Coronary Vessels/diagnostic imaging ; Coronary Vessels/drug effects* ; Coronary Vessels/pathology ; Diabetic Angiopathies/diagnosis ; Diabetic Angiopathies/therapy* ; Drug-Eluting Stents* ; Everolimus/administration & dosage ; Female ; Humans ; Male ; Middle Aged ; Neointima* ; Percutaneous Coronary Intervention/adverse effects ; Percutaneous Coronary Intervention/instrumentation* ; Pilot Projects ; Predictive Value of Tests ; Prosthesis Design ; Republic of Korea ; Risk Factors ; Sirolimus/administration & dosage ; Sirolimus/analogs & derivatives ; Time Factors ; Treatment Outcome ; Ultrasonography, Interventional*
diabetes mellitus ; everolimus-eluting stent ; intravascular ultrasound ; zotarolimus-eluting stent
OBJECTIVES: The aim of this study was to evaluate the extent of neointimal response after the implantation of a second-generation drug-eluting stent, zotarolimus-eluting stent (ZES-ER, Endeavor Resolute) or everolimus-eluting stent (EES, Xience V), using intravascular ultrasound (IVUS) in diabetic patients. MATERIALS AND METHODS: In all, 154 diabetic patients with de-novo coronary lesions were randomized to be implanted with a ZES-ER or EES, and the angiographic follow-up at 9 months combined with a complete IVUS study was available for 96 patients with 101 lesions. RESULTS: Baseline demographic and lesion parameters were similar in both groups at index percutaneous coronary intervention. On follow-up angiography, in-stent late lumen loss and minimal lumen diameter were not different between the two groups. On IVUS study, neointimal hyperplasia volume [median (interquartile range): ZES-ER vs. EES; 2.25 mm (0.57-6.25) vs. 1.59 mm (0.45-8.37), P=0.615] and in-stent percentage of volume obstruction [median (interquartile range): ZES-ER vs. EES; 1.16% (0.33-3.61) vs. 0.77% (0.29-4.01), P=0.615] showed similar results between the two groups. CONCLUSION: In diabetic patients, the second-generation drug-eluting stents, ZES-ER and EES, were comparable in inhibiting neointimal proliferation.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ko, Young Guk(고영국) ORCID logo https://orcid.org/0000-0001-7748-5788
Kwon, Hyuck Moon(권혁문) ORCID logo https://orcid.org/0000-0001-9901-5015
Min, Pil Ki(민필기) ORCID logo https://orcid.org/0000-0001-7033-7651
Won, Ho Youn(원호연)
Yoon, Young Won(윤영원) ORCID logo https://orcid.org/0000-0002-0907-0350
Lee, Byoung Kwon(이병권) ORCID logo https://orcid.org/0000-0001-9259-2776
Jang, Yang Soo(장양수) ORCID logo https://orcid.org/0000-0002-2169-3112
Hong, Bum Kee(홍범기) ORCID logo https://orcid.org/0000-0002-6456-0184
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.